Osteoporosis represents the most common human bone disorder with a large medical and economical burden on the Health Care System. Bisphosphonates are the major drugs used for the treatment of osteoporosis. Differences in their chemical structures and pharmacokinetic actions can explain the different clinical efficacy among these molecules. Risedronate is a potent inhibitor of farnesyl pyrophosphate synthase, but does not bind strongly to mineral; this lower mineral binding may enable risedronate to have a wider distribution in bone. Its antifracture efficacy has been established in several randomized phase III controlled studies that showed its value in the reduction of vertebral, non vertebral and hip fractures. Randomized controlled trials and observational studies demonstrated risedronate efficacy and safety in different subsets of patients, therefore risedronate is configured, among oral therapies currently available for osteoporosis, as a drug of first choice.

Risedronate's efficacy: from randomized clinical trials to real clinical practice / Iolascon, Giovanni; Sirico, Felice; Ferrante, Alberto; Gimigliano, Raffaele; Gimigliano, Francesca. - In: CLINICAL CASES IN MINERAL AND BONE METABOLISM. - ISSN 1724-8914. - 7:1(2010), pp. 19-22.

Risedronate's efficacy: from randomized clinical trials to real clinical practice

Sirico, Felice;
2010

Abstract

Osteoporosis represents the most common human bone disorder with a large medical and economical burden on the Health Care System. Bisphosphonates are the major drugs used for the treatment of osteoporosis. Differences in their chemical structures and pharmacokinetic actions can explain the different clinical efficacy among these molecules. Risedronate is a potent inhibitor of farnesyl pyrophosphate synthase, but does not bind strongly to mineral; this lower mineral binding may enable risedronate to have a wider distribution in bone. Its antifracture efficacy has been established in several randomized phase III controlled studies that showed its value in the reduction of vertebral, non vertebral and hip fractures. Randomized controlled trials and observational studies demonstrated risedronate efficacy and safety in different subsets of patients, therefore risedronate is configured, among oral therapies currently available for osteoporosis, as a drug of first choice.
2010
Risedronate's efficacy: from randomized clinical trials to real clinical practice / Iolascon, Giovanni; Sirico, Felice; Ferrante, Alberto; Gimigliano, Raffaele; Gimigliano, Francesca. - In: CLINICAL CASES IN MINERAL AND BONE METABOLISM. - ISSN 1724-8914. - 7:1(2010), pp. 19-22.
File in questo prodotto:
File Dimensione Formato  
Iolascon et al. - Risedronate's efficacy - from randomized clinical trials to real clinical practice.pdf

accesso aperto

Tipologia: Documento in Post-print
Licenza: Dominio pubblico
Dimensione 56.08 kB
Formato Adobe PDF
56.08 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/739095
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 9
  • ???jsp.display-item.citation.isi??? ND
social impact